Tyler Brous

Kayak Therapeutics, Inc., headquartered in Austin, Texas, is a development-stage biotechnology company dedicated to discovering and developing innovative therapies for patients with cancer. The company’s pipeline focuses on novel approaches targeting tumor-intrinsic signaling pathways to overcome resistance and improve patient outcomes. For more information, please visit www.kayaktherapeutics.com.

The affordable way to replace missing teeth without going to the dentist. Next The affordable way to replace missing teeth without going to the dentist. If you need dental implants, try ResetSmile. Start smiling more and chewing food better with our truly dentist-grade, flexible, removable device - without metal dentures or implant surgery. Reset your smile.

A mission equal parts scientific and humanitarian. CerSci Therapeutics is a clinical-stage biotechnology company developing non-opioid pharmaceuticals for the treatment of pain. With a focus on alleviating human suffering and rescuing society from the on-going opioid crisis, CerSci is poised to deliver a new generation of non-opioid medicines to treat acute postoperative pain and chronic neuropathic pain (e.g. painful diabetic neuropathy). CerSci's lead clinical candidate, CT-044, is currently in Phase I Safety and Tolerability Studies in human volunteers (Phase I).

Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina.

Kayak Therapeutics, Inc., headquartered in Austin, Texas, is a development-stage biotechnology company dedicated to discovering and developing innovative therapies for patients with cancer. The company’s pipeline focuses on novel approaches targeting tumor-intrinsic signaling pathways to overcome resistance and improve patient outcomes. For more information, please visit www.kayaktherapeutics.com.

BBK Capital is a multi-strategy investment firm. BBK Fund I, L.P. is an SBIC in partnership with the Small Business Administration and the Department of Defense. Our investments primarily focus on Critical Technologies and Industries at both the fund and company level.

The affordable way to replace missing teeth without going to the dentist. Next The affordable way to replace missing teeth without going to the dentist. If you need dental implants, try ResetSmile. Start smiling more and chewing food better with our truly dentist-grade, flexible, removable device - without metal dentures or implant surgery. Reset your smile.

Infleqtion, Inc. (NYSE: INFQ) is a global leader in quantum technology, delivering neutral atom solutions for quantum computing, networking, sensing, and security. With a product portfolio spanning quantum computers, quantum optical clocks, RF receivers, and inertial sensors, Infleqtion’s full-stack approach combines high-performance hardware with the company’s proprietary Superstaq quantum computing software platform. Infleqtion’s systems are already in use by the U.S. Department of War, NASA, the U.K. government, and in multiple collaborations with NVIDIA. Infleqtion, in collaboration with NVIDIA, published the world’s first demonstration of a materials science application using logical qubits. With operations in the U.S., Europe, and Asia, Infleqtion meets the demands of government and commercial customers across the space, defense, energy, finance and telecommunications sectors.

A mission equal parts scientific and humanitarian. CerSci Therapeutics is a clinical-stage biotechnology company developing non-opioid pharmaceuticals for the treatment of pain. With a focus on alleviating human suffering and rescuing society from the on-going opioid crisis, CerSci is poised to deliver a new generation of non-opioid medicines to treat acute postoperative pain and chronic neuropathic pain (e.g. painful diabetic neuropathy). CerSci's lead clinical candidate, CT-044, is currently in Phase I Safety and Tolerability Studies in human volunteers (Phase I).